Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
4 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Results By Year timeline is not available.
Page 1
Full population results from the core phase of CompLEEment-1, a phase 3b study of ribociclib plus letrozole as first-line therapy for advanced breast cancer in an expanded population.
Breast Cancer Res Treat. 2021 Oct;189(3):689-699. doi: 10.1007/s10549-021-06334-0. Epub 2021 Aug 19.
Breast Cancer Res Treat. 2021.
PMID: 34414532
Free PMC article.
Clinical Trial.
Correction to: Full population results from the core phase of CompLEEment-1, a phase 3b study of ribociclib plus letrozole as first-line therapy for advanced breast cancer in an expanded population.
De Laurentiis M, Borstnar S, Campone M, Warner E, Bofill JS, Jacot W, Dent S, Martin M, Ring A, Cottu P, Lu J, Ciruelos E, Azim HA, Chatterjee S, Zhou K, Wu J, Menon-Singh L, Zamagni C.
De Laurentiis M, et al. Among authors: menon singh l.
Breast Cancer Res Treat. 2022 Jan;191(1):223-224. doi: 10.1007/s10549-021-06374-6.
Breast Cancer Res Treat. 2022.
PMID: 34625861
Free PMC article.
No abstract available.
Item in Clipboard
Ribociclib plus letrozole in subgroups of special clinical interest with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: Subgroup analysis of the phase IIIb CompLEEment-1 trial.
Cottu P, Ring A, Abdel-Razeq H, Marchetti P, Cardoso F, Salvador Bofill J, Martín M, Menon-Singh L, Wu J, De Laurentiis M.
Cottu P, et al. Among authors: menon singh l.
Breast. 2022 Apr;62:75-83. doi: 10.1016/j.breast.2022.01.016. Epub 2022 Jan 31.
Breast. 2022.
PMID: 35131646
Free PMC article.
Clinical Trial.
Item in Clipboard
Ribociclib plus letrozole in male patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: subgroup analysis of the phase IIIb CompLEEment-1 trial.
Campone M, De Laurentiis M, Zamagni C, Kudryavcev I, Agterof M, Brown-Glaberman U, Palácová M, Chatterjee S, Menon-Singh L, Wu J, Martín M.
Campone M, et al. Among authors: menon singh l.
Breast Cancer Res Treat. 2022 May;193(1):95-103. doi: 10.1007/s10549-022-06543-1. Epub 2022 Feb 25.
Breast Cancer Res Treat. 2022.
PMID: 35212906
Clinical Trial.
Item in Clipboard
Cite
Cite